CAMBRIDGE, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer. “We are thrilled to welcome Dr. Khan to the Alkeus executive team as we pursue our mission to innovate transformative therapies for degenerative eye diseases,” said Leonide Saad, Ph.D., President and CEO at Alkeus.

马萨诸塞州剑桥市，2024年1月23日（环球通讯社）--Alkeus Pharmaceuticals，Inc.今天宣布，Seemi Khan，M.D.，M.P.H.，M.B.A.，已加入该公司担任首席医疗官。Alkeus总裁兼首席执行官Leonide Saad博士说：“我们很高兴欢迎Khan博士加入Alkeus执行团队，因为我们致力于创新退行性眼病的变革疗法。”。

“An accomplished executive, Dr. Khan has a track record in bringing rare disease treatments to patients in need across multiple therapeutic areas.” Prior to joining Alkeus, Dr. Khan served as Chief Medical Officer at Reata Pharmaceuticals through its acquisition by Biogen, where she oversaw all clinical programs from early stage to commercialization.

“作为一名有成就的高管，汗博士在多个治疗领域为有需要的患者提供罕见疾病治疗方面有着良好的记录。”在加入Alkeus之前，汗博士通过收购Biogen担任Reata Pharmaceuticals的首席医疗官，在那里她监督了从早期到商业化的所有临床项目。

Dr. Khan was instrumental in the approval and launch of the first treatment for Friedreich’s ataxia. Dr. Khan’s experience also includes senior leadership roles at Mitsubishi Tanabe Pharma America, Quark Pharmaceuticals, Abbott and AbbVie. An internist and nephrologist with expertise in rare disease, immunology and rheumatology, she has served as an Assistant Professor of Medicine at Tufts University School of Medicine.

Khan博士在批准并推出第一种治疗弗里德里希共济失调的方法方面发挥了重要作用。汗博士的经验还包括在三菱田边制药美国公司、夸克制药公司、雅培和雅培担任高级领导职务。她是一名内科医生和肾脏病专家，拥有罕见疾病、免疫学和风湿病方面的专业知识，曾担任塔夫茨大学医学院的医学助理教授。

She further has received an M.P.H. from Harvard T.H. Chan School of Public Health and an M.B.A. from Brandeis University. 'I am excited to join Alkeus, particularly at a time when gildeuretinol has shown promising advancement toward the treatment of Stargardt disease,” Dr. Khan said. “I’m eager to continue building the team to bring significant impact on the lives of individuals confronted with progressive vision loss.

她还获得了哈佛大学陈T.H.公共卫生学院的硕士学位和布兰代斯大学的工商管理硕士学位。”我很高兴加入Alkeus，特别是在gildeuretinol在治疗Stargardt病方面显示出有希望的进展之际，”Khan博士说。“我渴望继续建立团队，为面临渐进性视力丧失的个人的生活带来重大影响。

My commitment to medical innovation and patient care aligns seamlessly with Alkeus' mission, and I look forward to driving forward this life-changing treatment.' About Alkeus Pharmaceuticals Alkeus.

我对医疗创新和患者护理的承诺与Alkeus的使命无缝契合，我期待着推动这种改变生命的治疗关于Alkeus Pharmaceuticals Alkeus。